NanoViricides Refreshes ATM Capacity to $8.4M Under S-3 Float Cap
NNVC sits 36% above its 52-week low of $0.85.
Summary
NanoViricides reset its existing at-the-market program to allow up to $8.4M of additional share sales through D. Boral Capital, a large overhang for a company that just flagged going-concern doubt.
Key Events · Financing and Capital Events · NNVC
-
ATM Capacity Reset to $8.4M
Amendment No. 3 to the July 17, 2026 sales agreement lets NanoViricides sell up to $8,376,444 of common stock through or to D. Boral Capital as agent or principal.
-
Float Cap Drives the Limit
The ceiling is the S-3 General Instruction I.B.6 one-third-of-public-float limit: public float of $43,179,500 based on 25,550,000 non-affiliate shares at $1.69 as of the September 21, 2026 close.
-
Prior Sales Already Consumed Cap
About $6,016,722 of shares were already sold under I.B.6 in the trailing 12-month period, so this amendment refreshes remaining headroom rather than opening a new facility.
-
Going-Concern Backdrop
Filed one day after the 2026-11-16 10-Q, which reported a $5.7M quarterly loss, substantial doubt about ability to continue as a going concern, and the start of ATM share sales.
Analysis · NNVC · Life Sciences
This is Amendment No. 3 to a sales agreement first signed July 17, 2026 — not a new program. What changed is the size of the bucket: the company can now sell up to $8,376,444 of stock through D. Boral Capital, a limit set by the one-third-of-public-float rule because its $43.2M float is under $75M. Against a $29.6M market cap, that is a large overhang, and it lands one day after the 10-Q disclosed substantial doubt about continuing as a going concern and confirmed ATM sales had already started. Roughly $6.0M has already been sold under the cap in the trailing 12 months, so the practical read is continued drip-feed dilution to fund clinical spending rather than a one-time raise.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NNVC was trading at $1.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $29.6M. The 52-week trading range was $0.85 to $1.93. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.